Utidelone plus capecitabine versus standard taxane plus capecitabine
Part of Cancer, Skin clinical trials.
This Phase 3 study compares two chemotherapy combinations to treat HER2-negative breast cancer that has spread or is locally advanced. It aims to find which plan works better and has an acceptable side-effect profile for people who have had prior taxane treatment (in earlier-stage settings).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult woman (18+) who has breast cancer that is locally advanced or metastatic
- Your cancer test shows HER2-negative in both the main tumor and any sampled/biopsied metastases
- Your health and daily functioning are fairly good (ECOG score 0–2)
- Your cancer has measurable spots that can be tracked on scans (RECIST 1.1)
- You can take medicines by mouth, recover from prior treatment side effects to mild level (Grade 1 or less, with alopecia allowed)
- You must not have had certain recent treatments (including chemo/radiation/hormone/other anti-cancer therapies in the last 4 weeks)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares utidelone with docetaxel in people with HER2-negative advanced or metastatic breast cancer. It aims to see which treatment works better and is safer for controlling the cancer and helping patients live longer.
This trial looks at whether adding a chemotherapy medicine called capecitabine (taken in smaller, regular doses) to the standard after-surgery (adjuvant) treatment can lower the chance of cancer coming back in people with early-stage, high-risk HER2-positive breast cancer. It targets patients who still had cancer left after earlier treatment or who had higher-risk tumor features.
This trial tests a combination of two chemotherapy drugs, utidelone and capecitabine, for women with HER2-negative breast cancer that has spread to other parts of the body. The goal is to see if this combination can help shrink tumors and slow the cancer's growth.
This trial tests a combination of two oral chemotherapy drugs (Utidelone and Capecitabine) for women with triple-negative breast cancer that did not fully disappear after standard chemo before surgery. The goal is to see if this treatment can lower the chance of the cancer coming back.
This trial tests if the combination of Utidelone and capecitabine can shrink brain metastases in people with HER2-negative breast cancer. It is designed for those whose cancer has spread to the brain and who have not had many prior treatments.
This trial tests if adding UTD2 to capecitabine works better than capecitabine alone for triple-negative breast cancer that didn't completely disappear after chemo. It's for patients who had surgery and are at risk of cancer coming back.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.